Sign Out
No formal interaction studies with Actilyse and medicinal products commonly administered in patients with acute myocardial infarction have been performed.
Medicinal products that affect coagulation or those that alter platelet function may increase the risk of bleeding prior to, during or after Actilyse therapy.
Concomitant treatment with ACE inhibitors may enhance the risk of suffering an anaphylactoid reaction, as in the cases describing such reactions a relatively larger proportion of patients were receiving ACE inhibitors concomitantly.
